1. Market Research
  2. > Abscess – Pipeline Review, H1 2013

Abscess – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 47 pages

Abscess – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Abscess - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Abscess, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abscess. Abscess - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Abscess.
- A review of the Abscess products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Abscess pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Abscess.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Abscess pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Abscess - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Abscess Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Abscess 7
Abscess Therapeutics under Development by Companies 9
Abscess Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Abscess Therapeutics - Products under Development by Companies 14
Abscess Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Abscess Therapeutics Development 16
Novartis AG 16
Toyama Chemical Co. Ltd 17
Trius Therapeutics, Inc. 18
Durata Therapeutics Inc. 19
Abscess - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
pasireotide - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
dalbavancin - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
tedizolid phosphate - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
piperacillin sodium - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Drug For Staphylococcus aureus Infections - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Abscess Therapeutics - Drug Profile Updates 34
Abscess Therapeutics - Dormant Products 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47



List of Tables

Number of Products Under Development for Abscess, H1 2013 7
Products under Development for Abscess - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Novartis AG, H1 2013 16
Toyama Chemical Co. Ltd, H1 2013 17
Trius Therapeutics, Inc., H1 2013 18
Durata Therapeutics Inc., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Abscess Therapeutics - Drug Profile Updates 34
Abscess Therapeutics - Dormant Products 45



List of Figures

Number of Products under Development for Abscess, H1 2013 7
Products under Development for Abscess - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.